{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:04:44Z","timestamp":1791644684611,"version":"4.3.4"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.adro.2025.101917","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:28:14Z","timestamp":1760142494000},"page":"101917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lutetium 177Lu Vipivotide Tetraxetan Efficacy and Toxicity in Advanced Prostate Cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Anthony Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helaine","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3145-2953","authenticated-orcid":false,"given":"Andrew","family":"Salner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101917_bib0001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101917_bib0002","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101917_bib0003","article-title":"Lutetium Lu-177 dotatate flare reaction","volume":"6","author":"Salner","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101917_bib0004","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"Kafka","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.adro.2025.101917_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.630589","article-title":"Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer","volume":"11","author":"Vlachostergios","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2025.101917_bib0006","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00259-024-06856-x","article-title":"Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [(68)Ga]Ga-PSMA-11 PET scans of primary prostate cancer","volume":"52","author":"Rupp","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2025.101917_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1066926","article-title":"Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA","volume":"12","author":"Assadi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2025.101917_bib0008","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.3390\/cancers15123216","article-title":"Personalized [177Lu]lutetium-PSMA therapy for patients with pre-treated castration-resistant prostate cancer: A single institution experience from a comprehensive cancer centre","volume":"15","author":"Thaiss","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.adro.2025.101917_bib0009","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","year":"2023","journal-title":"Prostate"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:36:13Z","timestamp":1776875773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109425002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452109425002040"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101917","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lutetium 177Lu Vipivotide Tetraxetan Efficacy and Toxicity in Advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101917"}}